The effectiveness of two vectored ND vaccines (Innovax® ND and Vectormune® ND) was tested, in single and prime-boost vaccination programs, against challenge with velogenic NDV genotype VII, in eight chicken groups (G). G1 and G2 were control groups. G3-5 received Innovax® ND, while G6-8 received Vectormune® ND on the hatchery. Additionally, G4 and G7 received live La Sota two-weeks later, and G5 and G8 received inactivated vaccine one-week later. On the challenge day, G3 (Innovax® ND vaccine alone) had lower HI titer than G6 (Vectormune® ND vaccine alone) (p < 0.05). Boosting with inactivated vaccine instead of La Sota increased serological response. G3 had the same HI titer as G2 (positive control) but decreased viral shedding significantly after the 3rd day post challenge (d pc). G8 (Vectormune® ND plus inactivated vaccine) had 86.5 % decrease of viral shedding on the 3rd d pc, while that of G7 (Vectormune® ND plus La Sota) persisted until the 6th d pc. All regimens increased weight gain (p < 0.05), fully protected against mortality, and showed few clinical signs. Prime-boost vaccines provided significant reduction and time shortening of heterologous viral shedding.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cimid.2022.101836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice.
iScience
January 2025
National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
The importance of humoral immunity in combating TB has gained extensive recognition. In this study, a subunit vaccine named Ag85A-LpqH (AL) was prepared by fusing the antigen Ag85A proved to induce robust T cell immune responses, and LpqH was shown to produce protective antibodies. The prevention and BCG prime-boost mouse models were established to test the vaccine efficacy.
View Article and Find Full Text PDFAdenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses.
Vaccines (Basel)
January 2025
Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
An effective universal influenza vaccine is urgently needed to overcome the limitations of current seasonal influenza vaccines, which are ineffective against mismatched strains and unable to protect against pandemic influenza. In this study, bovine and human adenoviral vector-based vaccine platforms were utilized to express various combinations of antigens. These included the H5N1 hemagglutinin (HA) stem region or HA2, the extracellular domain of matrix protein 2 of influenza A virus, HA signal peptide (SP), trimerization domain, excretory peptide, and the autophagy-inducing peptide C5 (AIP-C5).
View Article and Find Full Text PDFDengue virus (DENV) remains a significant public health threat in tropical and subtropical regions, with effective antiviral treatments and vaccines still not fully established despite extensive research. A critical aspect of vaccine development for DENV involves selecting proteins from both structural and non-structural regions of the virus to activate humoral and cellular immune responses effectively. In this study, we developed a novel vaccine for dengue virus serotype 2 (DENV2) using a heterologous Prime-Boost strategy that combines an adenoviral vector (Ad) with subunit vaccines.
View Article and Find Full Text PDFAnti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens.
Sci Immunol
January 2025
Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.
Vaccination strategies against HIV-1 aim to elicit broadly neutralizing antibodies (bnAbs) using prime-boost regimens with HIV envelope (Env) immunogens. Epitope mapping has shown that early antibody responses are directed to easily accessible nonneutralizing epitopes on Env instead of bnAb epitopes. Autologously neutralizing antibody responses appear upon boosting, once immunodominant epitopes are saturated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!